RxDoctor Payments Data

Charles Richardson, MD

Ophthalmology · Hattiesburg, MSNPI 1568570117

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 53.8% of the total.

$3,379in general payments, 2019–2025

Across 171 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Ocular Therapeutix, Inc.$319
  • Aerie Pharmaceuticals, Inc.$303
  • Johnson & Johnson Surgical Vision, Inc.$229
  • Alcon$210
  • Novartis$100
  • plus $401 from 11 others

What the payments were for

  • Food & beverage$3,379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,379 in reported general payments places this provider in the 65th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$672,172
Medicare patients
2,263
Services billed
6,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost226$86,299
RestasisCyclosporine31$23,169
VyzultaLatanoprostene Bunod55$17,906
CombiganBrimonidine Tartrate/Timolol40$14,387
Prednisolone Acetate474$13,926
Latanoprost1,284$10,041
Alphagan PBrimonidine Tartrate36$8,771
Ketorolac Tromethamine442$6,179
Ofloxacin438$5,171
Brimonidine Tartrate178$4,569
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat137$2,491
Travoprost17$2,244
Fluorometholone14$1,148
Timolol Maleate119$806
ErythromycinErythromycin Base57$600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,818$132,626333 claims
Bausch & Lomb Americas Inc.Vyzulta$65$17,90655 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →